Gouty arthritis and uric acid metabolism

Current Opinion in Rheumatology

Volumn 8, Issue 3, 1996, Pages 248-254

  Wise, Christopher M ^a   Agudelo, Carlos A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

CORRELATION FUNCTION; CORTICOSTEROID THERAPY; DIURESIS; GOUT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; RISK FACTOR; URIC ACID URINE LEVEL;

EID: 0029945366     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199605000-00014     Document Type: Review

References (54)

1. Terkeltaub RA: Gout: questions that still need to be answered. Ann Rheum Dis 1995, 54:79-81. A brief review of unanswered questions about gout, including the evolutionary advantage to the loss of urate oxidase in humans, the molecular basis for urate underexcretion in most patients, and mechanisms for crystal-induced cell activation and inflammation.
2. Rosenthal AK, Ryan LM: Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995, 21:151-161.
3. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ: Racial differences in the incidence of gout. Arthritis Rheum 1995, 38:628-632. In this study of the incidence of gout in two cohorts of male medical students followed up for a mean of 28 years, the cumulative incidence of gout was 10.9% in blacks and 5.8% in whites. Systolic blood pressure in the black cohort was the only baseline characteristic predictive of the development of gout. The development of hypertension during the period of observation was an independent risk factor for the development of gout in both cohorts. Thiazide diuretic use could have been a major factor in the association of hypertension and gout.
4. Cassim B, Mody GM, Deenadayalu VK, Hammond MG: Gout in black South Africans: a clinical and genetic study. Ann Rheum Dis 1994, 53:759-762.
5. Simmonds HA, McBride MB, Hatfield PJ, Graham R, McCaskey J, Jackson M: Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol 1994, 33:932-937.
6. Harris CM, Lloyd DCEF, Lewis J: The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995, 48:1153-1158.
7. Cigolini M, Targher G, Tonoli M, Manara F, Muggeo M, De Sandre G: Hyperuricemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes 1995, 19:92-96.
8. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Higashino K: Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia. Ann Rheum Dis 1995, 54:351-354.
9. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K: Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout Ann Rheum Dis 1995, 54:90-93.
10. Fessel WJ, Siegelaub AB, Johnson ES: Correlates and consequences of asymptomatic hyperuricemia. Arch Intern Med 1973, 132:44-54.
11. Berger L, Yu TF: Renal function in gout: an analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975, 59:605-613.
12. Fessel WJ: Renal outcomes of gout and hyperuricemia. Am J Med 1979, 67:74-82.
13. Yu TF, Berger L: Impaired renal function in gout. Am J Med 1982, 72:95-100.
14. Beck LH: Requiem for gouty nephropathy. Kidney Int 1986, 30:280-287.
15. Tarng D-C, Lin H-Y, Shong M-L, Wang J-S, Yang W-C, Huang T-P: Renal function in gout patients. Am J Nephrol 1995, 15:31-37.
16. Levy FL, Adams-Huet B, Pak CYC: Ambulatory evaluation of nephrolithiasis: update of a 1980 protocol. Am J Med 1995, 98:50-59.
17. Ifudu O, Tan CC, Culin AL, Delano BG, Friedman EA: Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994, 23:347-351.
18. Youssef P, Brama T, York H, Pickard P, Stewart P, McGill N: Does renal impairment protect from gout? J Rheumatol 1995, 22:494-496. In a study of 40 hyperuricemic patients with normal serum creatinine and 40 with elevated creatinine, the prevalence of gout was similar in the two groups. Only about half of the patients with renal insufficiency were on dialysis, and the 53% prevalence of gout in the control group in this study appears exceedingly high.
19. Bertolo MB, Lavras-Costallat LT: Hiperuricemia e gota: experiencia em hemodialisados [in Spanish]. Rev Bras Reumatol 1995, 35:253-256. In a prospective evaluation of 25 patients on long-term hemodialysis, only two patients had acute monoarthritis during a mean follow-up of 24 months.
20. Zawadski J, Grenda R, Januszewicz P: Effect of nifedipine on tubular handling of uric acid in transplanted kidney on cyclosporine A treatment. Nephron 1995, 70:77-82.
21. Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, van der Woude FJ: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995, 345:610-614. In a study of 128 renal transplant patients, the incidence of gout was decreased from 13% in patients remaining on cyclosporine for 8 years compared with 2% in those switched to azathioprine 3 months after transplantation. A trend toward improved patient and graft survival and less hypertension was seen in the azathioprine group.
22. Evardsson VO, Kaiser BA, Polinsky MS, Palmer JA, Quien R, Baluarte HJ: Natural history and etiology of hyperuricemia following pediatric renal transplantation. Pediatr Nephrol 1995, 9:57-60. In a study of 81 pediatric transplant patients taking cyclosporine, hyperuricemic patients were older, had worse renal function, and required diuretics more often than normouricemic patients. Cyclosporine contributed relatively little to reducing the high frequency of asymptomatic hyperuricemia in this group, and diuretic use and reduced allograft function were more important.
23. Tak HK, Cooper SM, Wilcox WR: Studies on the nucleation of monosodium urate at 37°C. Arthritis Rheum 1980, 23:574-580.
24. Kam M, Perl-Treves D, Caspi D, Addadi L: Antibodies against crystals. FASEB J 1992, 6:2608-2613.
25. Kam M, Perl-Treves D, Sfez R, Addadi L: Specificity in the recognition of crystals by antibodies. J Mol Recognit 1994, 7:257-264. Monosodium urate crystals were found to be capable of inducing the formation of specific antibodies, which in turn can catalyze the more rapid formation of new crystals. The clinical importance of antibodies to urate in the context of previous studies remains to be investigated.
26. Gross M: Cristallographic antibodies. Nature 1995, 373:105-106. Discusses the potential for further characterization of antibodies against monosodium urate crystals to provide clues to some of the unanswered questions regarding the acute inflammatory process of the gouty attack.
27. Gathof BS, Jurgens D, Gresser U: Clinical symptoms of patients with partial HPRT deficiency. Adv Exp Med Biol 1994, 370:341-344.
28. Reiter L, Brown MA, Edmonds J: Familial hyperuricemic nephropathy. Am J Kidney Dis 1995, 25:235-241.
29. Porcelli B, Vannoni D, Leoncini R, Pizzichini M, Pagani R, Marinello E: Free oxypurines in plasma and urine of gout patients before and after a purine-free diet. Adv Exp Med Biol 1994, 370:47-52.
30. Puig JG, Mateos FA, Jimienez ML, Ramos TH: Renal excretion of hypoxanthine and xanthine in primary gout. Am J Med 1988, 85:533-537.
31. Kelsall JT, O'Hanlon DP: Gout during pregnancy. J Rheumatol 1994, 21:1365-1366.
32. Cohen MR: Proximal gout following renal transplantation [letter]. Arthritis Rheum 1994, 37:1709-1710.
33. Staub-Schmidt T, Chaouat A, Bloch JG, Christmann D: Spinal involvement in gout. Arthritis Rheum 1995, 38:139-141.
34. Fenton P, Young S, Prutis K: Gout of the spine: two case reports and a review of the literature. J Bone Joint Surg Am 1995, 77:767-771.
35. Murshid WR, Moss TH, Ettles DF, Cummins BH: Tophaceous gout of the spine causing spinal cord compression. Br J Neurosurg 1994, 8:751-754.
36. Disla E, Stein S, Acevedo M, Cuppari G: Gouty arthritis in the acquired immunodeficiency syndrome: an unusual but aggressive case. Arthritis Rheum 1995, 38:570-572. Possibly the first case of gout developing in a patient with AIDS was described, in this case with aggressive tophaceous disease, a poor response to indomethacin, but a good response to colchicine. Further reports will need to be reviewed before any conclusions can be drawn about the effects of the immunologic process in AIDS on the expression of gout and response to therapy.
37. Thomas E, Leroux JL, Serre I, Bonnel F, Mary H, Baldet P, Blotman F: Tophaceous gout of the patella with primary hyperparathyroidism. Clin Exp Rheumatol 1995, 13:263-265.
38. Recht MP, Seragini F, Kramer J, Dalinka MK, Hurtgen K, Resnick D: Isolated or dominant lesions of the patella in gout: a report of seven patients. Skeletal Radiol 1994, 23:113-116.
39. Kostman JR, Rush P, Reginato AJ: Granulomatous tophaceous gout mimicking tuberculous tenosynovitis: report of two cases. Clin Infect Dis 1995, 21:217-219.
40. Kraus A, Flores-Suarez LF: Acute gout associated with omeprazole. Lancet 1995, 345:461-462.
41. Craig MH, Poole GV, Hauser CJ: Postsurgical gout. Am Surg 1995, 61:56-59. The clinical features of acute gout occurring in the postsurgical setting were reviewed in 52 patients, 45 of whom had a history of gout. This report emphasizes the importance of crystal-induced arthritis in the differential diagnosis of fever developing after surgery.
42. Simkin PA, Bassett JE, Lee QP: Not water, but formalin, dissolves urate crystals in tophaceous tissue samples. J Rheumatol 1994, 21:2320-2321. Urate crystals were shown to persist in water and alcohol but dissolve in all but the highest concentrations of formalin, suggesting that a specific formaldehyde-urate interaction, and not water, is responsible for the dissolution of urate crystals observed in formalin-treated tissues.
43. Rigby AS, Wood PHN: Serum uric acid levels and gout: what does this herald for the population? Clin Exp Rheumatol 1994, 12:395-400. A history of podagra or abrupt attack in another joint proved to be the most useful criterion for diagnosing gout, whereas elevated serum uric acid and presence of tophi were poor discriminators. Serum urate levels were elevated in only 55% of patients with gout. The use of fasting urate levels and the apparent collection of data many years prior to the study, before diagnostic criteria were published, raises questions about the completeness of the data used in this study.
44. Blair JM, Sorensen LB, Arnsdorf MF, Lal R: The application of atomic force microscopy for the detection of microcrystals in synovial fluid from patients with recurrent synovitis. Semin Arthritis Rheum 1995, 24:359-369. A new technique for the detection of crystals in synovial fluid, atomic force microscopy, was described. This technique requires only a few microliters of sample and minimal sample preparation. The potential for this technique in clinical and laboratory research requires further study.
45. Siegel LB, Alloway JA, Nashel DJ: Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325-1327. A single dose of intramuscular corticotropin (40 units) was compared with triamcinolone acetonide (60 mg) in acute gout. Repeat injection was required in nine of 15 patients receiving corticotropin but only in five of 16 receiving triamcinolone, and many patients receiving corticotropin required a third injection to treat rebound attacks, suggesting greater efficacy for triamcinolone.
46. Ferraz MB: An evidence based appraisal of the management of nontophaceous interval gout [editorial]. J Rheumatol 1995, 22:1618-1620.
47. Fam AG: Should patients with interval gout be treated with urate lowering drugs? [editorial]. J Rheumatol 1995, 22:1621-1623.
48. Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, Rouzioux JM, Scherrmann J-M: Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 1995, 332:642-645. A case of apparent life-saving treatment of a colchicine overdose with colchicine-specific Fab fragments was reported. The infusion of Fab fragments resulted in a dramatic reversal of hypotension and improvement in cardiac output. A transient rise in total plasma colchicine was probably explained by the mobilization of colchicine from peripheral sites.
49. Ben-Chetrit E, Scherrmann J-M, Zylber-Katz E, Levy M: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994, 21:710-713. The potential risks of colchicine in patients with renal and liver disease were emphasized in an analysis of colchicine disposition in patients with familial Mediterranean fever. The plasma half-life of colchicine was found to increase from 4.4 hours in patients with normal renal function to 18.8 hours in patients with renal failure. A patient with end-stage renal disease and hepatic cirrhosis had a colchicine plasma half-life of 50 hours. Colchicine should be given with extreme caution in patients with renal disease, especially in those with concomitant liver disease.
50. Ferraz MB, O'Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995, 22:908-914. The cost effectiveness of urate-lowering drugs was analyzed in a decision analysis model. A cost of $237 was estimated to avert an additional attack every year in a cohort of patients with one attack per year. Treatment with urate-lowering drugs was estimated to be cost saving in patients having two or more attacks per year.
51. Moriwaki Y, Yamamoto T, Takahashi S, Suda M, Higashino K: Effect of glucose infusion on renal transport of purine bases and oxypurinol. Nephron 1995, 69:424-427.
52. Braden GL, Warzynski MJ, Golightly M, Ballow M: Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994, 70:145-151.
53. Day RO, Birkett KJ, Hicks M, Miners JO, Graham GG, Brooks PM: New uses for allopurinol. Drugs 1994, 48:339-344.
54. Montecucco C, Caporali R, Rossi S, Porta C: Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 1994, 37:777-778.